Melanoma vaccine reduces death or cancer recurrence by 42%

Forty-two percent is the sort of number that gets a drug fast-tracked, so the real test is whether the FDA treats it that way.

In a world-first international trial, adding intismeran, a type of personalized therapeutic cancer vaccine made from each patient's own tumor, to pembrolizumab immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%.

Read it at Medical Xpress ↗

← Front page